Multiple myeloma is a plasma cell dyscrasia. It is the second most common hematological malignancy which is characterized by proliferation of clonal plasma cells producing harmful monoclonal immunoglobulin. Despite treatment modalities greatly evolved during the last decade, small amount of aberrant residual cells reside in patients after therapy and can cause relapse of the disease. Characterization of the residual, resistant clones can help to reveal important therapeutic targets for application of effective and precious treatment. We use CD38, CD45, CD56 and CD19 sorted aberrant plasma cells to perform next generation sequencing of their exome. Among the 213 genes in which at least one variant was present, the most interesting was found gene NRAS, one of the most often mutated gene in multiple myeloma, and homologs of 88 gene panel previously used for multiple myeloma sequencing among which was a gene previously identified as gene meaningful in bortezomib resistance. Nevertheless, the results of next generation exome sequencing need to be interpreted with caution, since they rely on bioinformatical analysis, which is still being optimized. The results of next generation sequencing will also have to be confirmed by Sanger sequencing. Final results supported by larger cohort of patients will be published soon.
Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease
- Authors: Martina Zátopková; Jana Filipová; MUDr. Tomáš Jelínek; MUDr. Petr Vojta; Mgr. Tereza Ševčíková, Ph.D.; RNDr. Michal Šimíček , Ph.D.; Mgr. Lucie Říhová, PhD.; Mgr. Renata Bezděková; Mgr. Kateřina Growková; Mgr. Zuzana Kufová; Mgr. Jana Smejkalová, Ph.D.; doc. MUDr. Marián Hajdúch, Ph.D.; Doc.MUDr. Luděk Pour, Ph.D.; MUDr. Jiří Minařík, Ph.D. ; MUDr. Alexandra Jungová; Doc. MUDr. Vladimír Maisnar, Ph.D.; MUDr. Fedor Kryukov; prof. MUDr. Roman Hájek, CSc.